GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

The cancer cachexia therapeutics market is gaining traction due to the rising global cancer burden and high prevalence of cachexia in advanced-stage ...

The global cervical cancer treatment market is poised for significant expansion, with a new market analysis projecting its value to grow from an estimated USD 9.2 billion in 2025 to USD 15.9 billion ...

GlaxoSmithKline Pharmaceuticals reports a 12% increase in net profit to Rs 279 crore for the June quarter despite a slight ...

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

GlaxoSmithKline Pharmaceuticals to launch oncology assets Jemperli and Zejula in India, addressing critical unmet needs in ...

Pharma giant Glaxosmithkline, which has major operations in Upper Providence and West Point, is partnering with China-based ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

By Lauren Ohnesorge – Senior Staff Writer, Triangle Business Journal Aug 8, 2012 ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.